Objective: This randomised clinical trial evaluated the survival rate of resin-based restorations in Class I and Class II beveled preparations in primary molars, over 48 months.
Methods: Forty-eight children received 141 restorations in beveled cavosurface margin preparations in primary molars randomly assigned by a lottery method: 46 received treatment with Vitremer Tri-Cure Glass Ionomer System (33 Class I and 13 Class II restorations); 51 received treatment with Freedom (36 Class I and 15 Class II restorations); 44 received treatment with TPH Spectrum (30 Class I and 14 Class II restorations). Two calibrated examiners (weight kappa> or =0.85) evaluated the restorations using the modified USPHS criteria and visible plaque index score at baseline and after 12, 24, 36 and 48 months. Cox regression with survival analysis and logistic regression evaluated the clinical performance of restorations.
Results: After 48 months, 11 teeth had exfoliated, 16 restorations were dropouts, 83 restorations were clinically successful of which 26 had used Vitremer, 32 had used Freedom and 25 had used TPH Spectrum. Thirty-one restorations failed because of secondary caries, fractures and loss of retention. The cumulative survival was 73.9%, 83.4% and 79.6%, respectively for Vitremer, Freedom and THP Spectrum with no differences among materials (Log Rank Mantel-Cox, p>0.05). However, the Class II cavity preparation reduced the survival of the restorations (OR=5.1) for all materials evaluated (p>0.05).
Conclusions: The life expectancy of Vitremer, Freedom and THP Spectrum in Class I and Class II restorations could be comparable after 48 months.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jdent.2010.02.004 | DOI Listing |
CA Cancer J Clin
January 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly BRCA alterations, display enhanced sensitivity to these agents because of synthetic lethality induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications.
View Article and Find Full Text PDFRep Prog Phys
January 2025
SISSA, via Bonomea 265, 34136 Trieste, Trieste, 34136, ITALY.
We review recent progress regarding the double scaled Sachdev-Ye-Kitaev model and other p-local quantum mechanical random Hamiltonians. These models exhibit an expansion using chord diagrams, which can be solved by combinatorial methods. We describe exact results in these models, including their spectrum, correlation functions, and Lyapunov exponent.
View Article and Find Full Text PDFCytometry B Clin Cytom
January 2025
Department of Pediatrics, Section of Allergy and Immunology, University of Colorado School of Medicine, Aurora, Colorado, USA.
A reduced proportion of peripheral class-switched memory B cells (CSM-B cells) is presumed to indicate ineffective germinal activity. The extent that this finding corresponds to a plausible germinal center failure pathophysiology in patients not diagnosed with CVID or hyper IgM syndrome is not known. We asked if patients with low CSM-B cells are more likely to demonstrate failure to produce serum IgA and IgG than counterparts with nonreduced class-switched memory B cell levels, regardless of diagnosis.
View Article and Find Full Text PDFCurr Med Chem
January 2025
School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Branched-chain amino acids (BCAAs) are essential amino acids for humans and play an indispensable role in many physiological and pathological processes. Branched-chain amino acid aminotransferase (BCAT) is a key enzyme that catalyzes the metabolism of BCAAs. BCAT is upregulated in many cancers and implicated in the development and progress of some other diseases, such as metabolic and neurological diseases; and therefore, targeting BCAT might be a potential therapeutic approach for these diseases.
View Article and Find Full Text PDFCurr Drug Targets
January 2025
Department of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL33458, United States.
Diseases affecting bone encompass a spectrum of disorders, from prevalent conditions such as osteoporosis and Paget's disease, collectively impacting millions, to rare genetic disorders including Fibrodysplasia Ossificans Progressiva (FOP). While several classes of drugs, such as bisphosphonates, synthetic hormones, and antibodies, are utilized in the treatment of bone diseases, their efficacy is often curtailed by issues of tolerability and high incidence of adverse effects. Developing therapeutic agents for bone diseases is hampered by the fact that numerous pathways regulating bone metabolism also perform pivotal functions in other organ systems.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!